Autres langues Werewolf Therapeutics, Inc.

Actions

HOWL

US95075A1079

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 01/05/2024			Varia. 5j.	Varia. 1 janv.
6,02 ^USD	-3,53%		-5,79%	+55,96%

23/04	Werewolf Therapeutics, Inc. présente ses premières données précliniques sur les molécules IL-10 INDUKINE en tant que traitement potentiel des maladies inflammatoires de l'intestin lors de la réunion annuelle de l'AAI.	CI
05/04	Werewolf Therapeutics, Inc. présente des résultats précliniques démontrant les effets anti-tumoraux de cytokines pro-inflammatoires.	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	24/04
Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting	23/04
Werewolf Therapeutics, Inc. Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease at AAI Annual Meeting	23/04
Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting	05/04
Werewolf Therapeutics, Inc. Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics	05/04
Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting	04/04
Werewolf Therapeutics' Q4 Net Loss Narrows	07/03
Werewolf Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	07/03
Werewolf Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	07/03
Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference	06/03
Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024	05/03
Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook	08/01
Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors	04/01
Werewolf Therapeutics, Inc. Appoints Michael Atkins to its Board of Directors	04/01
Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference	22/11
North American Morning Briefing : Stocks Seen -2-	15/11
Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update	14/11
Werewolf Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Sector Update: Health Care Stocks Stronger Late Afternoon	03/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Werewolf Therapeutics, Inc.

Actions

HOWL

US95075A1079

Autres langues

Filtres